All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
GLOW trial: 5-year follow-up of first-line fixed-duration ibrutinib plus venetoclax in older adults with CLL/SLL
Bookmark this article
|
The phase III GLOW trial (NCT03462719) assessed the safety and efficacy of first-line fixed-duration Ibr + Ven vs Clb + Obi in older adults with CLL/SLL.1 The Lymphoma Hub previously reported the 4-year follow-up outcomes from the GLOW trial. The 5-year follow-up results of this trial were presented at the SOHO 2024 Annual Meeting by Munir.1 |
| Key learnings |
| The estimated 54-month PFS rate was higher in the Ibr + Ven arm vs Clb + Obi arm (67% vs 20%; HR, 0.256). |
| OS was higher and sustained at 57 months in the Ibr + Ven arm vs Clb + Obi arm (HR, 0.453; p = 0.0038). |
| The need for second-line therapy was lower by 82% in the Ibr + Ven arm (HR, 0.185; 95% CI, 0.096–0.355; p < 0.0001). |
| Long-term data from the GLOW trial demonstrate the durable efficacy and tolerable safety profile of Ibr + Ven, supporting its use in older adults with CLL/SLL. |
Abbreviations: CI, confidence interval; Clb, chlorambucil; CLL, chronic lymphocytic leukemia; Ibr, ibrutinib; Obi, obinutuzumab; OS, overall survival; PFS, progression-free survival; SLL, small lymphocytic lymphoma; SOHO, Society of Hematologic Oncology; Ven, venetoclax.
- Munir T. First-line fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab: Up to 5 years of follow-up from the GLOW study. Poster #CLL-487. Presented at: Society of Hematologic Oncology 2024 Annual Meeting; Sep 4–7, 2024; Houston, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
2 votes - 20 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox